Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Novavax’s closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug ...

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full ...

US biopharma Novavax (Nasdaq: NVAX) closed 20% higher on Wednesday after announcing an update on its COVID-19 vaccine. The US ...

The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.

The company said the FDA issued a formal information request tied to its Biologics License Application (BLA) and asked for a ...

Here’s what several large drugmakers said about tariffs when reporting earnings this morning: Merck made a small downward ...

Recent US news is marked by upheaval in governmental bodies and key policy shifts. This includes significant firings in the ...